We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Read MoreHide Full Article
Biogen Inc. (BIIB - Free Report) announced that the FDA has granted Fast Track designation for its investigational therapy, aducanumab, for the treatment of early-stage Alzheimer’s disease (AD).
We note that the FDA grants Fast Track status to facilitate the development and expedite the review process for candidates that are being developed for the treatment of serious conditions with unmet medical need.
Aducanumab is in two global phase III studies – ENGAGE and EMERGE – to evaluate its safety and efficacy in slowing cognitive impairment and progression of disability in patients suffering from early-stage AD.
Biogen is also evaluating aducanumab in a phase 1b study (PRIME) to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical effects of the candidate in patients with prodromal or mild AD. Data from the PRIME study demonstrated that aducanumab reduced amyloid-beta in the brain and the reduction was dose dependent.
We remind investors that in Jun 2016, aducanumab was accepted into the European Medicines Agency’s (EMA) Priority Medicines (PRIME) program, which aims to bring treatments to patients faster by enhancing the agency’s support for the development of investigational medicines for diseases without available treatment or in need for better treatment options.
While successful development of therapies for Alzheimer’s disease is quite challenging, the market represents huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched.
Last month, Eli Lilly and Company (LLY - Free Report) and AstraZeneca plc (AZN - Free Report) gained fast track status in the U.S. for their experimental AD treatment, AZD3293.
AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor, is currently in phase III studies. In addition to the phase II/III study – AMARANTH, patients are being enrolled in a phase III study – DAYBREAK-ALZ, which is evaluating the safety and efficacy of the candidate in people with mild Alzheimer's dementia.
Biogen currently has a Zacks Rank #3 (Buy). Anika Therapeutics Inc. (ANIK - Free Report) is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Biogen Inc. (BIIB - Free Report) announced that the FDA has granted Fast Track designation for its investigational therapy, aducanumab, for the treatment of early-stage Alzheimer’s disease (AD).
We note that the FDA grants Fast Track status to facilitate the development and expedite the review process for candidates that are being developed for the treatment of serious conditions with unmet medical need.
Aducanumab is in two global phase III studies – ENGAGE and EMERGE – to evaluate its safety and efficacy in slowing cognitive impairment and progression of disability in patients suffering from early-stage AD.
Biogen is also evaluating aducanumab in a phase 1b study (PRIME) to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical effects of the candidate in patients with prodromal or mild AD. Data from the PRIME study demonstrated that aducanumab reduced amyloid-beta in the brain and the reduction was dose dependent.
We remind investors that in Jun 2016, aducanumab was accepted into the European Medicines Agency’s (EMA) Priority Medicines (PRIME) program, which aims to bring treatments to patients faster by enhancing the agency’s support for the development of investigational medicines for diseases without available treatment or in need for better treatment options.
While successful development of therapies for Alzheimer’s disease is quite challenging, the market represents huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched.
BIOGEN INC Price
BIOGEN INC Price | BIOGEN INC Quote
Last month, Eli Lilly and Company (LLY - Free Report) and AstraZeneca plc (AZN - Free Report) gained fast track status in the U.S. for their experimental AD treatment, AZD3293.
AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor, is currently in phase III studies. In addition to the phase II/III study – AMARANTH, patients are being enrolled in a phase III study – DAYBREAK-ALZ, which is evaluating the safety and efficacy of the candidate in people with mild Alzheimer's dementia.
Biogen currently has a Zacks Rank #3 (Buy). Anika Therapeutics Inc. (ANIK - Free Report) is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>